February 9, 2018 / 1:32 PM / 10 months ago

BRIEF-Intellipharmaceutics Meets With FDA Regarding Oxycodone Er NDA Development Program

Feb 9 (Reuters) - Intellipharmaceutics International Inc :

* INTELLIPHARMACEUTICS MEETS WITH FDA REGARDING OXYCODONE ER NDA DEVELOPMENT PROGRAM

* INTELLIPHARMACEUTICS INTERNATIONAL - BASED ON MEETING WITH FDA, OXYCODONE ER WILL NO LONGER INCLUDE THE BLUE DYE IN IT

* INTELLIPHARMACEUTICS INTERNATIONAL- FDA CONFIRMED REMOVAL OF BLUE DYE IN OXYCODONE ER UNLIKELY TO HAVE IMPACT ON ITS FORMULATION QUALITY, PERFORMANCE

* INTELLIPHARMACEUTICS INTERNATIONAL - WILL NOT BE REQUIRED TO REPEAT IN VIVO BIOEQUIVALENCE STUDIES & PHARMACOKINETIC STUDIES SUBMITTED IN OXYCODONE ER NDA

* INTELLIPHARMACEUTICS - FDA SAID, FROM ABUSE LIABILITY PERSPECTIVE,CATEGORY 1 STUDIES WILL NOT HAVE TO BE REPEATED ON OXYCODONE ER WITHOUT BLUE DYE Source text: (bit.ly/2EwSmcQ) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below